Research Radar, News & Live Feeds | SGCB Research Initiative

Live Intelligence Hub

Real-Time Scientific Feeds

Query: SGCB OR LGMD2E OR "beta-sarcoglycan" • Direct from NCBI / NLM Loading live papers...

Editorial Analyses

Curated Research Deep Dives

Comprehensive scientific syntheses reviewing pivotal clinical trial data, emerging genetic methodologies, and regulatory developments.

Clinical Milestone • Phase 3 NCT06246513

Phase 3 EMERGENE Meets Primary Day-60 Biopsy Endpoint for SRP-9003 in LGMD2E/R4

Pivotal results from Sarepta's global, open-label Phase 3 EMERGENE trial evaluating systemic IV infusion of bidridistrogene xeboparvovec (SRP-9003) at 7.41 × 10¹³ vg/kg demonstrate robust protein expression across both ambulatory and non-ambulatory cohorts:

• Ambulatory Cohort (n=11): Mean change of +43.4% percent positive fibers (PPF, P < .001).

• Non-Ambulatory Cohort (n=6): Mean change of +23.9% PPF (P < .02).

• Durability: Phase 1/2 cohorts maintain motor stability across 4–5 years.

Source: World Muscle Society (WMS) & MDA Clinical & Scientific Conferences.

Preclinical Editing • In Vivo Adenine Base Editing (ABE)

In Vivo Base Editing Potential: Feasibility Analysis of ABE for SGCB c.341C>T (p.Ser114Phe)

Because c.341C>T is a canonical transition mutation ($C \cdot G \to T \cdot A$), it represents an ideal candidate for precision Adenine Base Editing (ABE). Rather than introducing double-strand DNA breaks like classical CRISPR-Cas9, an evolved deoxyadenosine deaminase fused to Cas9 nickase deaminates the antisense adenine:

• Mechanism: Antisense A → Inosine (read as G) → scarless C·G restoration.

• Safety: Zero double-strand breaks; no indel mutagenesis or chromosomal translocations.

• Impact: Fully rescues wild-type Ser114 ectodomain trafficking.

Scientific Benchmark: Preclinical neuromuscular ABE proof-of-concept pipelines.

Vectorology • Delivery Frontiers SORT LNPs & eVLPs

Overcoming the AAV Single-Dose Barrier: Muscle-Targeted Non-Viral Delivery

A major therapeutic dilemma in systemic AAV gene therapies is that neutralizing antibody (NAb) induction precludes redosing. Academic and biotech consortia are pioneering non-viral alternatives for muscular dystrophies:

• SORT LNPs: Selective Organ Targeting lipid nanoparticles engineered to biodistribute specifically to skeletal muscle and cardiomyocytes.

• Engineered Virus-Like Particles (eVLPs): Deliver transient base-editor RNPs with zero permanent viral DNA, eliminating oncogenic integration and allowing re-administration.

Literature Benchmark: Nature Biotechnology & Cell non-viral gene delivery roadmaps.

Consortium Study • Regulatory Science GRASP-LGMD Consortium

GRASP-LGMD Consortium: Establishing Quantitative MRI (T1/ECV) & NSAA as Trial Standards

The Global Research In Action for Sarcoglycanopathies (GRASP-LGMD) consortium has standardized natural history endpoints across international centers, establishing critical benchmarks for regulatory submissions:

• Quantitative MRI: Thigh muscle water T2 and fat fraction (Dixon MRI) track subclinical fibro-fatty replacement with extreme sensitivity.

• Cardiac Monitoring: Extracellular volume fraction (ECV) and early troponin elevation predict myocardial fibrosis prior to ejection fraction decline.

Collaborating Groups: CureLGMD2E Foundation, MDA, and European Neuromuscular Centre (ENMC).